Top Markets
#1 Black Phoenix Black Phoenix +21,279.43%
#2 Nesa Nesa +680.24%
#3 Ontology Gas Ontology Gas +79.73%
#4 Kinesis Silver Kinesis Silver +54.00%
#5 Biconomy Biconomy +38.09%
#6 QuantixAI QuantixAI +23.11%
#7 EXOD EXOD +22.78%
#8 Magma Finance Magma Finance +18.80%
#9 SAFEcoin SAFEcoin +18.27%
#10 BNB Attestation Service BNB Attestation Service +18.17%
Coin of the day
Black Phoenix Black Phoenix
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Camurus AB Camurus AB

Camurus AB

CAMX
Xếp hạng trong cổ phiếu #4179
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Giá cổ phiếu
$67.97
Vốn hóa thị trường
$4.04B
Thay đổi (1 ngày)
-1.06%
Thay đổi (1 năm)
-7.50%
Quốc gia
SE
Giao dịch Camurus AB (CAMX)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Camurus AB (CAMX)
Giá đóng cửa cao nhất: $69.18 vào 2026-08-01

Giá đóng cửa thấp nhất: $7.87 vào 2015-12-01
Lịch sử giá cổ phiếu của Camurus AB từ 2015 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 0.49%
2025 26.88%
2024 4.43%
2023 92.92%
2022 53.39%
2021 -24.41%
2020 143.97%
2019 -13.20%
2018 -26.98%
2017 23.80%
2016 45.06%
2015 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.93 42.03%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 48.01%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $147.42 496.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.62 -12.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $766.55 6.54%
CH